A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Status:
Active, not recruiting
Trial end date:
2021-11-22
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to establish the dose of verinurad combined
with allopurinol 300 mg once daily that will elicit the desired response; ie, reduction in
urinary albumin to creatinine ratio (UACR) at 6 months.